世界のドラベ症候群治療市場2023年~2027年

【英語タイトル】Global Dravet Syndrome Treatment Market 2023-2027

Technavioが出版した調査資料(IRTNTR45344-23)・商品コード:IRTNTR45344-23
・発行会社(調査会社):Technavio
・発行日:2022年12月30日
・ページ数:163
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社は、世界のドラベ症候群治療市場規模が2022年から2027年まで年平均9.6%成長し、575.14百万ドルに達すると予測しています。本調査レポートでは、ドラベ症候群治療の世界市場について広く調査・分析を行い、エグゼクティブサマリー、市場状況、市場規模、過去の市場規模、ファイブフォース分析、製品別(SGD、TGD、FDG)分析、販売チャネル別(病院薬局、小売店、Eコマース、その他)分析、顧客状況、地域別状況(北米、ヨーロッパ、アジア太平洋、アメリカ、イギリス、ドイツ、中国、日本、その他地域)分析、推進要因・課題・動向、企業状況、企業分析などの項目を掲載しています。なお、本書には、AbbVie Inc.、BIOCODEX SAS、Cadila Healthcare Ltd.、Encoded Therapeutics Inc.、Epygenix Therapeutics Inc.、H Lundbeck AS、Jazz Pharmaceuticals Plc、Johnson and Johnson、Lupin Ltd.、PTC Therapeutics Inc.、Stoke Therapeutics Inc.、Sun Pharmaceutical Industries Ltd.、Supernus Pharmaceuticals Inc.、Takeda Pharmaceutical Co. Ltd.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模
・過去の市場規模
・ファイブフォース分析

・世界のドラベ症候群治療市場規模:製品別
- SGDの市場規模
- TGDの市場規模
- FDGの市場規模

・世界のドラベ症候群治療市場規模:販売チャネル別
- 病院薬局の市場規模
- 小売店の市場規模
- Eコマースの市場規模
- その他販売チャネルの市場規模

・顧客状況

・地域別状況
- 北米のドラベ症候群治療市場規模
- ヨーロッパのドラベ症候群治療市場規模
- アジア太平洋のドラベ症候群治療市場規模
- アメリカのドラベ症候群治療市場規模
- イギリスのドラベ症候群治療市場規模
- ドイツのドラベ症候群治療市場規模
- 中国のドラベ症候群治療市場規模
- 日本のドラベ症候群治療市場規模
- その他地域のドラベ症候群治療市場規模

・推進要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要なパラメーターを分析することにより、また複数のソースからのデータを調査、統合、および合計することにより、市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、正確な市場の成長を予測するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選択方法と分析を提供します。

世界のドラベ症候群治療市場 2023-2027年

Technavio社は、ドラベ症候群治療市場をモニターしており、2022年から2027年にかけて575.14百万ドルの成長が予測され、予測期間中のCAGRは9.6%で加速すると予測しています。当レポートでは、ドラベ症候群治療市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、特別な規制指定の増加、新製品上市の増加、DS治療のための遺伝子治療薬の進歩によって牽引されています。

Technavio社のドラベ症候群治療市場は以下のように分類されます:

・製品別:
- SGD
- TGD
- FDG

・流通チャネル別:
- 病院薬局
- 小売薬局
- 電子商取引
- その他

・地域別:
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間のドラベ症候群治療市場の成長を牽引する主な要因の一つとして、新世代の薬剤の使用増加が挙げられます。また、生物医学の進歩や強力なパイプラインが市場の大きな需要につながるとしています。

Technavio社は、複数の情報源から入手したデータを調査、統合、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、ドラベ症候群治療市場について以下の調査・分析を行います:
- ドラベ症候群治療市場規模
- ドラベ症候群治療市場予測
- ドラベ症候群治療市場産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., UCB SA, Viatris Inc., and Xenon Pharmaceuticals Incなどの企業情報が含まれています。また、ドラベ症候群治療市場分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global dravet syndrome treatment market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global dravet syndrome treatment market 2017 – 2021 ($ million)
o 4.2 Product Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 SGDs – Market size and forecast 2022-2027
o Exhibit 34: Chart on SGDs – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on SGDs – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on SGDs – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on SGDs – Year-over-year growth 2022-2027 (%)
o 6.4 TGDs – Market size and forecast 2022-2027
o Exhibit 38: Chart on TGDs – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on TGDs – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on TGDs – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on TGDs – Year-over-year growth 2022-2027 (%)
o 6.5 FDGs – Market size and forecast 2022-2027
o Exhibit 42: Chart on FDGs – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on FDGs – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on FDGs – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on FDGs – Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Product
o Exhibit 46: Market opportunity by Product ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 47: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 48: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 49: Chart on Comparison by Distribution Channel
o Exhibit 50: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacy – Market size and forecast 2022-2027
o Exhibit 51: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacy – Market size and forecast 2022-2027
o Exhibit 55: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o 7.5 E- Commerce – Market size and forecast 2022-2027
o Exhibit 59: Chart on E- Commerce – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on E- Commerce – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on E- Commerce – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on E- Commerce – Year-over-year growth 2022-2027 (%)
o 7.6 Others – Market size and forecast 2022-2027
o Exhibit 63: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Distribution Channel
o Exhibit 67: Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 69: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 71: Chart on Geographic comparison
o Exhibit 72: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 73: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 89: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 105: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 106: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 107: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 108: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 109: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 110: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 112: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 113: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 114: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 115: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 116: AbbVie Inc. – Overview
o Exhibit 117: AbbVie Inc. – Product / Service
o Exhibit 118: AbbVie Inc. – Key news
o Exhibit 119: AbbVie Inc. – Key offerings
o 12.4 BIOCODEX SAS
o Exhibit 120: BIOCODEX SAS – Overview
o Exhibit 121: BIOCODEX SAS – Product / Service
o Exhibit 122: BIOCODEX SAS – Key offerings
o 12.5 Encoded Therapeutics Inc.
o Exhibit 123: Encoded Therapeutics Inc. – Overview
o Exhibit 124: Encoded Therapeutics Inc. – Product / Service
o Exhibit 125: Encoded Therapeutics Inc. – Key offerings
o 12.6 Epygenix Therapeutics Inc.
o Exhibit 126: Epygenix Therapeutics Inc. – Overview
o Exhibit 127: Epygenix Therapeutics Inc. – Product / Service
o Exhibit 128: Epygenix Therapeutics Inc. – Key offerings
o 12.7 H Lundbeck AS
o Exhibit 129: H Lundbeck AS – Overview
o Exhibit 130: H Lundbeck AS – Product / Service
o Exhibit 131: H Lundbeck AS – Key offerings
o 12.8 Jazz Pharmaceuticals Plc
o Exhibit 132: Jazz Pharmaceuticals Plc – Overview
o Exhibit 133: Jazz Pharmaceuticals Plc – Product / Service
o Exhibit 134: Jazz Pharmaceuticals Plc – Key news
o Exhibit 135: Jazz Pharmaceuticals Plc – Key offerings
o 12.9 Johnson and Johnson
o Exhibit 136: Johnson and Johnson – Overview
o Exhibit 137: Johnson and Johnson – Business segments
o Exhibit 138: Johnson and Johnson – Key news
o Exhibit 139: Johnson and Johnson – Key offerings
o Exhibit 140: Johnson and Johnson – Segment focus
o 12.10 Lupin Ltd.
o Exhibit 141: Lupin Ltd. – Overview
o Exhibit 142: Lupin Ltd. – Product / Service
o Exhibit 143: Lupin Ltd. – Key news
o Exhibit 144: Lupin Ltd. – Key offerings
o 12.11 PTC Therapeutics Inc.
o Exhibit 145: PTC Therapeutics Inc. – Overview
o Exhibit 146: PTC Therapeutics Inc. – Business segments
o Exhibit 147: PTC Therapeutics Inc. – Key offerings
o Exhibit 148: PTC Therapeutics Inc. – Segment focus
o 12.12 Stoke Therapeutics Inc.
o Exhibit 149: Stoke Therapeutics Inc. – Overview
o Exhibit 150: Stoke Therapeutics Inc. – Product / Service
o Exhibit 151: Stoke Therapeutics Inc. – Key offerings
o 12.13 Sun Pharmaceutical Industries Ltd.
o Exhibit 152: Sun Pharmaceutical Industries Ltd. – Overview
o Exhibit 153: Sun Pharmaceutical Industries Ltd. – Product / Service
o Exhibit 154: Sun Pharmaceutical Industries Ltd. – Key offerings
o 12.14 Supernus Pharmaceuticals Inc.
o Exhibit 155: Supernus Pharmaceuticals Inc. – Overview
o Exhibit 156: Supernus Pharmaceuticals Inc. – Product / Service
o Exhibit 157: Supernus Pharmaceuticals Inc. – Key offerings
o 12.15 Takeda Pharmaceutical Co. Ltd.
o Exhibit 158: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 159: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 160: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 161: Takeda Pharmaceutical Co. Ltd. – Key offerings
o 12.16 UCB SA
o Exhibit 162: UCB SA – Overview
o Exhibit 163: UCB SA – Product / Service
o Exhibit 164: UCB SA – Key offerings
o 12.17 Viatris Inc.
o Exhibit 165: Viatris Inc. – Overview
o Exhibit 166: Viatris Inc. – Business segments
o Exhibit 167: Viatris Inc. – Key offerings
o Exhibit 168: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 169: Inclusions checklist
o Exhibit 170: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 171: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 172: Research methodology
o Exhibit 173: Validation techniques employed for market sizing
o Exhibit 174: Information sources
o 13.5 List of abbreviations
o Exhibit 175: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global dravet syndrome treatment market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Product – Market share 2022-2027 (%)
Exhibits31: Data Table on Product – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on SGDs – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on SGDs – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on SGDs – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on SGDs – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on TGDs – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on TGDs – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on TGDs – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on TGDs – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on FDGs – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on FDGs – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on FDGs – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on FDGs – Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Product ($ million)
Exhibits47: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits48: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits49: Chart on Comparison by Distribution Channel
Exhibits50: Data Table on Comparison by Distribution Channel
Exhibits51: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on E- Commerce – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on E- Commerce – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on E- Commerce – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on E- Commerce – Year-over-year growth 2022-2027 (%)
Exhibits63: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits67: Market opportunity by Distribution Channel ($ million)
Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits69: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits71: Chart on Geographic comparison
Exhibits72: Data Table on Geographic comparison
Exhibits73: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits105: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits106: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits107: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits108: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits109: Market opportunity By Geographical Landscape ($ million)
Exhibits110: Impact of drivers and challenges in 2022 and 2027
Exhibits111: Overview on Criticality of inputs and Factors of differentiation
Exhibits112: Overview on factors of disruption
Exhibits113: Impact of key risks on business
Exhibits114: Vendors covered
Exhibits115: Matrix on vendor position and classification
Exhibits116: AbbVie Inc. – Overview
Exhibits117: AbbVie Inc. – Product / Service
Exhibits118: AbbVie Inc. – Key news
Exhibits119: AbbVie Inc. – Key offerings
Exhibits120: BIOCODEX SAS – Overview
Exhibits121: BIOCODEX SAS – Product / Service
Exhibits122: BIOCODEX SAS – Key offerings
Exhibits123: Encoded Therapeutics Inc. – Overview
Exhibits124: Encoded Therapeutics Inc. – Product / Service
Exhibits125: Encoded Therapeutics Inc. – Key offerings
Exhibits126: Epygenix Therapeutics Inc. – Overview
Exhibits127: Epygenix Therapeutics Inc. – Product / Service
Exhibits128: Epygenix Therapeutics Inc. – Key offerings
Exhibits129: H Lundbeck AS – Overview
Exhibits130: H Lundbeck AS – Product / Service
Exhibits131: H Lundbeck AS – Key offerings
Exhibits132: Jazz Pharmaceuticals Plc – Overview
Exhibits133: Jazz Pharmaceuticals Plc – Product / Service
Exhibits134: Jazz Pharmaceuticals Plc – Key news
Exhibits135: Jazz Pharmaceuticals Plc – Key offerings
Exhibits136: Johnson and Johnson – Overview
Exhibits137: Johnson and Johnson – Business segments
Exhibits138: Johnson and Johnson – Key news
Exhibits139: Johnson and Johnson – Key offerings
Exhibits140: Johnson and Johnson – Segment focus
Exhibits141: Lupin Ltd. – Overview
Exhibits142: Lupin Ltd. – Product / Service
Exhibits143: Lupin Ltd. – Key news
Exhibits144: Lupin Ltd. – Key offerings
Exhibits145: PTC Therapeutics Inc. – Overview
Exhibits146: PTC Therapeutics Inc. – Business segments
Exhibits147: PTC Therapeutics Inc. – Key offerings
Exhibits148: PTC Therapeutics Inc. – Segment focus
Exhibits149: Stoke Therapeutics Inc. – Overview
Exhibits150: Stoke Therapeutics Inc. – Product / Service
Exhibits151: Stoke Therapeutics Inc. – Key offerings
Exhibits152: Sun Pharmaceutical Industries Ltd. – Overview
Exhibits153: Sun Pharmaceutical Industries Ltd. – Product / Service
Exhibits154: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibits155: Supernus Pharmaceuticals Inc. – Overview
Exhibits156: Supernus Pharmaceuticals Inc. – Product / Service
Exhibits157: Supernus Pharmaceuticals Inc. – Key offerings
Exhibits158: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits159: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits160: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits161: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits162: UCB SA – Overview
Exhibits163: UCB SA – Product / Service
Exhibits164: UCB SA – Key offerings
Exhibits165: Viatris Inc. – Overview
Exhibits166: Viatris Inc. – Business segments
Exhibits167: Viatris Inc. – Key offerings
Exhibits168: Viatris Inc. – Segment focus
Exhibits169: Inclusions checklist
Exhibits170: Exclusions checklist
Exhibits171: Currency conversion rates for US$
Exhibits172: Research methodology
Exhibits173: Validation techniques employed for market sizing
Exhibits174: Information sources
Exhibits175: List of abbreviations



★調査レポート[世界のドラベ症候群治療市場2023年~2027年] (コード:IRTNTR45344-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のドラベ症候群治療市場2023年~2027年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆